Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ganot

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Molecular Genetics & Genomic Medicine|March 23, 2021
Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophyHolly L Peay, Ryan Fischer, Brennan Mange, et al.
Orphanet Journal of Rare Diseases|May 11, 2019
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patientsRyan S Paquin, Ryan Fischer, Carol Mansfield, et al.
Neuromuscular Disorders : NMD|December 27, 2022
Clinical potential of microdystrophin as a surrogate endpointJessica F Boehler, Kristy J Brown, Margaret Beatka, et al.
Journal of Neuromuscular Diseases|August 2, 2024
Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular DystrophyHeidi Cope, Ryan Fischer, Emma Heslop, et al.
European Journal of Medical Genetics|October 11, 2025
Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UKHolly Peay, Ryan Fischer, Megan McNiff, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Molecular Genetics & Genomic Medicine|March 23, 2021
Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophyHolly L Peay, Ryan Fischer, Brennan Mange, et al.
Orphanet Journal of Rare Diseases|May 11, 2019
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patientsRyan S Paquin, Ryan Fischer, Carol Mansfield, et al.
Neuromuscular Disorders : NMD|December 27, 2022
Clinical potential of microdystrophin as a surrogate endpointJessica F Boehler, Kristy J Brown, Margaret Beatka, et al.
Journal of Neuromuscular Diseases|August 2, 2024
Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular DystrophyHeidi Cope, Ryan Fischer, Emma Heslop, et al.
European Journal of Medical Genetics|October 11, 2025
Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UKHolly Peay, Ryan Fischer, Megan McNiff, et al.
Pageof 7